For citizens

For companies

For medical specialists

PRAC investigates cancer medicine docetaxel

The PRAC is investigating the cancer medicine docetaxel following cases of neutropenic enterocolitis in patients in France. Most of the patients were being treated for operable breast cancer.

A preliminary assessment by the PRAC indicates that the frequency of this known side effect has not increased in the last two years. A thorough evaluation of available data is being carried out and final conclusions will be published once the review has been completed.

More detailed information on:

Pharmacovigilance Risk Assessment Committee (PRAC): 6-9 March 2017

SSL Certificates